2024
A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults
Kao C, Rostad C, Nolan L, Peters E, Kleinhenz J, Sherman J, Tippett A, Shih J, Yildirim I, Agbakoba V, Beresnev T, Ballou C, Kamidani S, Karmali V, Natrajan M, Scherer E, Rouphael N, Anderson E. A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults. The Journal Of Infectious Diseases 2024, 230: 1093-1101. PMID: 38536442, PMCID: PMC11565884, DOI: 10.1093/infdis/jiae148.Peer-Reviewed Original ResearchHealthy US adultsDouble-blindThird dosePlacebo-Controlled Clinical TrialSystemic reactionsHepatitis E virus vaccineUS adultsHepatitis E vaccinePlacebo groupPlacebo-controlledAdverse eventsE vaccineSecond doseClinical trialsDay 1Immune responseDosePhase 1ImmunogenicityMonthsSafety studiesVaccineInfant mortalityTrialsAdults
2019
Effect of Concomitant Antibiotic and Vaccine Administration on Serologic Responses to Rotavirus Vaccine
Anderson EJ, Lopman B, Yi J, Libster R, Creech CB, El-Khorazaty J, Baqar S, Yildirim I, Kao C, Rouphael N, Shane AL, Edwards K. Effect of Concomitant Antibiotic and Vaccine Administration on Serologic Responses to Rotavirus Vaccine. Journal Of The Pediatric Infectious Diseases Society 2019, 9: 479-482. PMID: 31237948, PMCID: PMC7495907, DOI: 10.1093/jpids/piz044.Peer-Reviewed Original Research